LyphoMed Inc said forming new division , called IPHARM , develop full line generic proprietary ophthalmic pharmaceutical .
Lyphomed said initial phase division produce product exclusively 200 mln dlr hospital use market .
The company said next phase IPHARM extend market include hospital non-hospital customer estimate valued 800 mln dlrs 1 billion dlrs total .
Ultimately , Lyphomed said IPHARM concentrate developing new proprietary ophthalmic dosage form .
Lyphomed said division already submitted Abbreviated New Drug Applications Food Drug Administration submit several within next six month .
Lyphomed said division operate Melrose Park manufacturing facility headed Ramesh Acharya , Lyphomed vice president general manager .
Reuter & # 3 ; 